AR128711A1 - Métodos para tratar carcinoma microcítico de pulmón - Google Patents
Métodos para tratar carcinoma microcítico de pulmónInfo
- Publication number
- AR128711A1 AR128711A1 ARP230100553A ARP230100553A AR128711A1 AR 128711 A1 AR128711 A1 AR 128711A1 AR P230100553 A ARP230100553 A AR P230100553A AR P230100553 A ARP230100553 A AR P230100553A AR 128711 A1 AR128711 A1 AR 128711A1
- Authority
- AR
- Argentina
- Prior art keywords
- lung carcinoma
- pharmaceutically acceptable
- acceptable salt
- methods
- wee1 inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen métodos para tratar carcinoma microcítico de pulmón (SCLC) usando un inhibidor de WEE1. Reivindicación 1: Un inhibidor de WEE1 para utilizar en el tratamiento del carcinoma microcítico de pulmón (SCLC) en un paciente que lo necesita. Reivindicación 2: Un inhibidor de WEE1 para usar de acuerdo con la reivindicación 1, en el cual el inhibidor de WEE1 es un compuesto que tiene la fórmula (1), o una sal farmacéuticamente aceptable suya. Reivindicación 3: Un inhibidor de WEE1 para usar de acuerdo con la reivindicación 1 o 2, en el cual dicho inhibidor de WEE1 se utiliza en combinación con carboplatino y/o etopósido. Reivindicación 22: Etopósido o una sal farmacéuticamente aceptable suya para utilizar en el tratamiento del carcinoma microcítico de pulmón (SCLC) en un paciente que lo necesita, en el cual el etopósido se utiliza en combinación con el compuesto que tiene la fórmula (1) o una sal farmacéuticamente aceptable suya y, opcionalmente, carboplatino, preferentemente, en la cual el uso es tal como se describe en cualquiera de las reivindicaciones 3 a 19. Reivindicación 23: Carboplatino para utilizar en el tratamiento del carcinoma microcítico de pulmón (SCLC) en un paciente que lo necesita, en el cual el carboplatino se utiliza en combinación con el compuesto que tiene la fórmula (1) o una sal farmacéuticamente aceptable suya y, opcionalmente, etopósido o una sal farmacéuticamente aceptable suya, en la cual el uso es tal como se describe en cualquiera de las reivindicaciones 3 a 19.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22160556 | 2022-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128711A1 true AR128711A1 (es) | 2024-06-05 |
Family
ID=80682926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100553A AR128711A1 (es) | 2022-03-07 | 2023-03-07 | Métodos para tratar carcinoma microcítico de pulmón |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4489756A1 (es) |
| JP (1) | JP2025509278A (es) |
| KR (1) | KR20240158972A (es) |
| CN (1) | CN118843466A (es) |
| AR (1) | AR128711A1 (es) |
| AU (1) | AU2023232376A1 (es) |
| CA (1) | CA3253688A1 (es) |
| IL (1) | IL315441A (es) |
| MX (1) | MX2024010900A (es) |
| TW (1) | TW202337469A (es) |
| WO (1) | WO2023170065A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025186213A1 (en) * | 2024-03-04 | 2025-09-12 | Debiopharm International S.A. | Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor |
| CN118581045A (zh) * | 2024-07-29 | 2024-09-03 | 云南省肿瘤医院(昆明医科大学第三附属医院) | 一株多突变的人小细胞肺癌淋巴结转移原代细胞系及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8436004B2 (en) | 2007-06-15 | 2013-05-07 | Msd K.K. | Bicycloaniline derivative |
| CN104271576A (zh) | 2012-02-23 | 2015-01-07 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
| EP3543242B1 (en) * | 2016-11-16 | 2024-01-03 | Impact Therapeutics (Shanghai), Inc | 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6h)-ketone compound |
| GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2022155202A1 (en) | 2021-01-13 | 2022-07-21 | Schrödinger, Inc. | Fused heterocycles and uses of same |
| WO2022188802A1 (en) * | 2021-03-10 | 2022-09-15 | Impact Therapeutics (Shanghai) , Inc | Use of wee1 kinase inhibitors in the treatment of cancer |
| AU2022287033B2 (en) | 2021-06-04 | 2025-04-17 | Aprea Therapeutics, Inc. | Pyridopyrimidine derivatives useful as wee1 kinase inhibitors |
| CN118338905A (zh) * | 2021-11-26 | 2024-07-12 | 上海瑛派药业有限公司 | Wee1激酶抑制剂在治疗癌症中的应用 |
-
2023
- 2023-03-07 WO PCT/EP2023/055751 patent/WO2023170065A1/en not_active Ceased
- 2023-03-07 EP EP23716186.4A patent/EP4489756A1/en active Pending
- 2023-03-07 AU AU2023232376A patent/AU2023232376A1/en active Pending
- 2023-03-07 MX MX2024010900A patent/MX2024010900A/es unknown
- 2023-03-07 CA CA3253688A patent/CA3253688A1/en active Pending
- 2023-03-07 CN CN202380026002.5A patent/CN118843466A/zh active Pending
- 2023-03-07 TW TW112108359A patent/TW202337469A/zh unknown
- 2023-03-07 IL IL315441A patent/IL315441A/en unknown
- 2023-03-07 AR ARP230100553A patent/AR128711A1/es unknown
- 2023-03-07 KR KR1020247033425A patent/KR20240158972A/ko active Pending
- 2023-03-07 JP JP2024553365A patent/JP2025509278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202337469A (zh) | 2023-10-01 |
| KR20240158972A (ko) | 2024-11-05 |
| WO2023170065A1 (en) | 2023-09-14 |
| AU2023232376A1 (en) | 2024-10-10 |
| IL315441A (en) | 2024-11-01 |
| MX2024010900A (es) | 2024-09-17 |
| JP2025509278A (ja) | 2025-04-11 |
| CN118843466A (zh) | 2024-10-25 |
| EP4489756A1 (en) | 2025-01-15 |
| CA3253688A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
| AR128711A1 (es) | Métodos para tratar carcinoma microcítico de pulmón | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| MX2023002233A (es) | Compuestos fosfolipidos y usos de estos. | |
| CL2023001062A1 (es) | Compuestos fosfolípidos y usos de estos | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| PE20242201A1 (es) | Tratamiento de neurofibromas cutaneos con mirdametinib | |
| CO2022006965A2 (es) | Inhibidores de egfr | |
| ECSP055854A (es) | Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| AR131842A1 (es) | Métodos para tratar gliomas | |
| AR127165A1 (es) | Resmetirom para reducir el volumen del hígado | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| MX2025002228A (es) | Metodos para el tratamiento o la profilaxis de la endometriosis | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| MX2023010849A (es) | Métodos de tratamiento. | |
| AR133820A1 (es) | Combinación de un inhibidor de wee1 y un inhibidor de pkmyt1 | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| AR132852A1 (es) | Combiterapia para tratar el cáncer | |
| CL2024003468A1 (es) | Inhibidores de ripk1 y métodos de uso. | |
| CL2025000332A1 (es) | Tratamiento de la urticaria con inhibidores de jak. |